Published in Mol Ther Nucleic Acids on June 17, 2014
DEK-targeting DNA aptamers as therapeutics for inflammatory arthritis. Nat Commun (2017) 1.39
Nucleic Acid Ligands With Protein-like Side Chains: Modified Aptamers and Their Use as Diagnostic and Therapeutic Agents. Mol Ther Nucleic Acids (2014) 1.09
Oligonucleotide Therapies: The Past and the Present. Hum Gene Ther (2015) 0.91
The tumor-suppressive and potential therapeutic functions of miR-34a in epithelial carcinomas. Expert Opin Ther Targets (2015) 0.82
Cross-protection of influenza A virus infection by a DNA aptamer targeting the PA endonuclease domain. Antimicrob Agents Chemother (2015) 0.81
Progress and Challenges in Developing Aptamer-Functionalized Targeted Drug Delivery Systems. Int J Mol Sci (2015) 0.81
Fit for the Eye: Aptamers in Ocular Disorders. Nucleic Acid Ther (2016) 0.80
Aptamer-nanoparticle complexes as powerful diagnostic and therapeutic tools. Exp Mol Med (2016) 0.80
Peptide aptamers: development and applications. Curr Top Med Chem (2015) 0.80
High throughput sequencing analysis of RNA libraries reveals the influences of initial library and PCR methods on SELEX efficiency. Sci Rep (2016) 0.79
Aptamer-miRNA-212 Conjugate Sensitizes NSCLC Cells to TRAIL. Mol Ther Nucleic Acids (2016) 0.79
Aptamer-Mediated Targeted Delivery of Therapeutics: An Update. Pharmaceuticals (Basel) (2016) 0.79
Therapeutic aptamers: developmental potential as anticancer drugs. BMB Rep (2015) 0.79
Oligonucleotide aptamer-drug conjugates for targeted therapy of acute myeloid leukemia. Biomaterials (2015) 0.79
Nanoscaled aptasensors for multi-analyte sensing. Bioimpacts (2014) 0.79
Oligonucleotide aptamers: A next-generation technology for the capture and detection of circulating tumor cells. Methods (2015) 0.78
Modular Assembly of Cell-targeting Devices Based on an Uncommon G-quadruplex Aptamer. Mol Ther Nucleic Acids (2015) 0.78
A New Transferrin Receptor Aptamer Inhibits New World Hemorrhagic Fever Mammarenavirus Entry. Mol Ther Nucleic Acids (2016) 0.78
Barriers to inhaled gene therapy of obstructive lung diseases: A review. J Control Release (2016) 0.77
Development of Nonviral Vectors Targeting the Brain as a Therapeutic Approach For Parkinson's Disease and Other Brain Disorders. Mol Ther (2015) 0.77
The aptamer-siRNA conjugates: reprogramming T cells for cancer therapy. Ther Deliv (2015) 0.77
From selection hits to clinical leads: progress in aptamer discovery. Mol Ther Methods Clin Dev (2016) 0.77
Therapeutic aptamers march on. Mol Ther Nucleic Acids (2014) 0.76
Aptamer technology for tracking cells' status & function. Mol Cell Ther (2014) 0.76
siRNA nanoparticles: the future of RNAi therapeutics for oncology? Nanomedicine (Lond) (2014) 0.76
Aptamer-siRNA Chimeras: Discovery, Progress, and Future Prospects. Biomedicines (2017) 0.76
Programmable biomaterials for dynamic and responsive drug delivery. Exp Biol Med (Maywood) (2016) 0.75
Improved Synthesis and In Vitro Evaluation of an Aptamer Ribosomal Toxin Conjugate. Nucleic Acid Ther (2016) 0.75
Quantitative PCR analysis of DNA aptamer pharmacokinetics in mice. Nucleic Acid Ther (2014) 0.75
Manipulating the in vivo immune response by targeted gene knockdown. Curr Opin Immunol (2015) 0.75
Aptamer-functionalized hybrid nanoparticle for the treatment of breast cancer. Eur J Pharm Biopharm (2017) 0.75
Synergistic Effects of Gold Nanocages in Hyperthermia and Radiotherapy Treatment. Nanoscale Res Lett (2016) 0.75
Arresting the colonial destiny of metastatic seeds with DNA aptamers. Mol Ther (2015) 0.75
Aptamers in Therapeutics. J Clin Diagn Res (2016) 0.75
Characterization of the specific interaction between the DNA aptamer sgc8c and protein tyrosine kinase-7 receptors at the surface of T-cells by biosensing AFM. Anal Bioanal Chem (2017) 0.75
Targeting Th17 Cells with Small Molecules and Small Interference RNA. Mediators Inflamm (2015) 0.75
Structural computational modeling of RNA aptamers. Methods (2016) 0.75
Selection and Characterization of an α6β4 Integrin blocking DNA Aptamer. Mol Ther Nucleic Acids (2016) 0.75
Toward the Selection of Cell Targeting Aptamers with Extended Biological Functionalities to Facilitate Endosomal Escape of Cargoes. Biomedicines (2017) 0.75
Aptamer Cell-Based Selection: Overview and Advances. Biomedicines (2017) 0.75
Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature (1998) 72.56
Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase. Science (1990) 35.96
In vitro selection of RNA molecules that bind specific ligands. Nature (1990) 30.19
Knocking down barriers: advances in siRNA delivery. Nat Rev Drug Discov (2009) 12.46
Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma. Science (1994) 10.45
The promises and pitfalls of RNA-interference-based therapeutics. Nature (2009) 7.53
Targeted nanoparticle-aptamer bioconjugates for cancer chemotherapy in vivo. Proc Natl Acad Sci U S A (2006) 6.90
Interfering with disease: a progress report on siRNA-based therapeutics. Nat Rev Drug Discov (2007) 6.37
Cell type-specific delivery of siRNAs with aptamer-siRNA chimeras. Nat Biotechnol (2006) 6.30
Drug delivery and targeting. Nature (1998) 6.16
Aptamers as therapeutics. Nat Rev Drug Discov (2010) 5.36
Aptamers evolved from live cells as effective molecular probes for cancer study. Proc Natl Acad Sci U S A (2006) 5.35
Selection in vitro of an RNA enzyme that specifically cleaves single-stranded DNA. Nature (1990) 5.02
Nanoparticle-aptamer bioconjugates: a new approach for targeting prostate cancer cells. Cancer Res (2004) 4.56
Identification and characterization of nuclease-stabilized RNA molecules that bind human prostate cancer cells via the prostate-specific membrane antigen. Cancer Res (2002) 4.16
Formulation of functionalized PLGA-PEG nanoparticles for in vivo targeted drug delivery. Biomaterials (2006) 4.09
Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease. Nat Rev Drug Discov (2006) 4.03
Precise engineering of targeted nanoparticles by using self-assembled biointegrated block copolymers. Proc Natl Acad Sci U S A (2008) 3.80
Systemic administration of optimized aptamer-siRNA chimeras promotes regression of PSMA-expressing tumors. Nat Biotechnol (2009) 3.78
Ligand-targeted therapeutics in anticancer therapy. Nat Rev Cancer (2002) 3.75
Current prospects for RNA interference-based therapies. Nat Rev Genet (2011) 3.63
Targeted delivery of cisplatin to prostate cancer cells by aptamer functionalized Pt(IV) prodrug-PLGA-PEG nanoparticles. Proc Natl Acad Sci U S A (2008) 3.62
Antibody targeted drugs as cancer therapeutics. Nat Rev Drug Discov (2006) 3.08
Novel dual inhibitory function aptamer-siRNA delivery system for HIV-1 therapy. Mol Ther (2008) 2.79
Aptamer mediated siRNA delivery. Nucleic Acids Res (2006) 2.77
Retracted Neutralizing aptamers from whole-cell SELEX inhibit the RET receptor tyrosine kinase. PLoS Biol (2005) 2.77
MUC1, the renaissance molecule. J Mammary Gland Biol Neoplasia (2001) 2.67
Aptamers generated from cell-SELEX for molecular medicine: a chemical biology approach. Acc Chem Res (2010) 2.48
An aptamer-doxorubicin physical conjugate as a novel targeted drug-delivery platform. Angew Chem Int Ed Engl (2006) 2.38
Discovery and development of the G-rich oligonucleotide AS1411 as a novel treatment for cancer. Exp Mol Pathol (2009) 2.25
Aptamer:toxin conjugates that specifically target prostate tumor cells. Cancer Res (2006) 2.23
Multivalent 4-1BB binding aptamers costimulate CD8+ T cells and inhibit tumor growth in mice. J Clin Invest (2008) 2.18
The chemical biology of aptamers. Angew Chem Int Ed Engl (2009) 2.09
Dendrimers in drug research. Chem Soc Rev (2003) 2.09
Antiproliferative activity of G-rich oligonucleotides correlates with protein binding. J Biol Chem (1999) 2.05
Selection, characterization and application of new RNA HIV gp 120 aptamers for facile delivery of Dicer substrate siRNAs into HIV infected cells. Nucleic Acids Res (2009) 2.02
An aptamer-siRNA chimera suppresses HIV-1 viral loads and protects from helper CD4(+) T cell decline in humanized mice. Sci Transl Med (2011) 1.93
SELEX with modified nucleotides. Curr Opin Chem Biol (2008) 1.92
Inhibition of HIV transmission in human cervicovaginal explants and humanized mice using CD4 aptamer-siRNA chimeras. J Clin Invest (2011) 1.92
Cell-specific internalization study of an aptamer from whole cell selection. Chemistry (2008) 1.81
RNAi and small interfering RNAs in human disease therapeutic applications. Trends Biotechnol (2010) 1.80
Impact of tumor hypoxia and anemia on radiation therapy outcomes. Oncologist (2002) 1.78
Preclinical safety and pharmacokinetic profile of ferumoxtran-10, an ultrasmall superparamagnetic iron oxide magnetic resonance contrast agent. Invest Radiol (2006) 1.77
Induction of tumour immunity by targeted inhibition of nonsense-mediated mRNA decay. Nature (2010) 1.73
Molecular assembly of an aptamer-drug conjugate for targeted drug delivery to tumor cells. Chembiochem (2009) 1.73
Aptamers evolved from cultured cancer cells reveal molecular differences of cancer cells in patient samples. Clin Chem (2007) 1.69
Superparamagnetic iron oxide nanoparticle-aptamer bioconjugates for combined prostate cancer imaging and therapy. ChemMedChem (2008) 1.57
Therapeutic RNA aptamers in clinical trials. Eur J Pharm Sci (2012) 1.56
DNA aptamer-micelle as an efficient detection/delivery vehicle toward cancer cells. Proc Natl Acad Sci U S A (2009) 1.56
Clathrin-mediated endocytosis of MUC1 is modulated by its glycosylation state. Mol Biol Cell (2000) 1.51
Reversible cell-specific drug delivery with aptamer-functionalized liposomes. Angew Chem Int Ed Engl (2009) 1.50
Delivery of chemo-sensitizing siRNAs to HER2+-breast cancer cells using RNA aptamers. Nucleic Acids Res (2012) 1.47
Prostate-targeted radiosensitization via aptamer-shRNA chimeras in human tumor xenografts. J Clin Invest (2011) 1.46
Microfluidic system for studying the interaction of nanoparticles and microparticles with cells. Anal Chem (2005) 1.45
Co-delivery of hydrophobic and hydrophilic drugs from nanoparticle-aptamer bioconjugates. ChemMedChem (2007) 1.42
Monolayer coated gold nanoparticles for delivery applications. Adv Drug Deliv Rev (2011) 1.36
In vivo selection of tumor-targeting RNA motifs. Nat Chem Biol (2009) 1.36
Nonequilibrium capillary electrophoresis of equilibrium mixtures: a universal tool for development of aptamers. J Am Chem Soc (2005) 1.32
Assembly of aptamer switch probes and photosensitizer on gold nanorods for targeted photothermal and photodynamic cancer therapy. ACS Nano (2012) 1.32
Detection and plasma pharmacokinetics of an anti-vascular endothelial growth factor oligonucleotide-aptamer (NX1838) in rhesus monkeys. J Chromatogr B Biomed Sci Appl (1999) 1.29
Targeting cancer cells with nucleic acid aptamers. Trends Biotechnol (2010) 1.26
An RNA alternative to human transferrin: a new tool for targeting human cells. Mol Ther Nucleic Acids (2012) 1.25
Cell-specific induction of apoptosis by rationally designed bivalent aptamer-siRNA transcripts silencing eukaryotic elongation factor 2. Curr Cancer Drug Targets (2008) 1.24
Regulation of singlet oxygen generation using single-walled carbon nanotubes. J Am Chem Soc (2008) 1.23
Molecular imaging of a cancer-targeting theragnostics probe using a nucleolin aptamer- and microRNA-221 molecular beacon-conjugated nanoparticle. Biomaterials (2011) 1.22
Aptamer-based endocytosis of a lysosomal enzyme. Proc Natl Acad Sci U S A (2008) 1.21
Aptamer-based tumor-targeted drug delivery for photodynamic therapy. ACS Nano (2010) 1.19
Nanovector delivery of siRNA for cancer therapy. Cancer Gene Ther (2012) 1.19
Non-SELEX selection of aptamers. J Am Chem Soc (2006) 1.18
Tumor targeted quantum dot-mucin 1 aptamer-doxorubicin conjugate for imaging and treatment of cancer. J Control Release (2011) 1.18
Targeting 4-1BB costimulation to disseminated tumor lesions with bi-specific oligonucleotide aptamers. Mol Ther (2011) 1.17
CELL-SELEX: Novel perspectives of aptamer-based therapeutics. Int J Mol Sci (2008) 1.17
Stable RNA nanoparticles as potential new generation drugs for cancer therapy. Adv Drug Deliv Rev (2013) 1.15
Pharmacokinetics and safety of an anti-vascular endothelial growth factor aptamer (NX1838) following injection into the vitreous humor of rhesus monkeys. Pharm Res (2000) 1.14
Cutting edge: novel RNA ligands able to bind CD4 antigen and inhibit CD4+ T lymphocyte function. J Immunol (1998) 1.11
Molecular aptamers for drug delivery. Trends Biotechnol (2011) 1.11
Functional in vivo delivery of multiplexed anti-HIV-1 siRNAs via a chemically synthesized aptamer with a sticky bridge. Mol Ther (2012) 1.10
Cell-specific aptamer-mediated targeted drug delivery. Oligonucleotides (2010) 1.10
Novel HER2 aptamer selectively delivers cytotoxic drug to HER2-positive breast cancer cells in vitro. J Transl Med (2012) 1.10
Directed evolution of gold nanoparticle delivery to cells. Chem Commun (Camb) (2009) 1.09
Near-infrared light-triggered, targeted drug delivery to cancer cells by aptamer gated nanovehicles. Adv Mater (2012) 1.08
Aptamer-conjugated and doxorubicin-loaded unimolecular micelles for targeted therapy of prostate cancer. Biomaterials (2013) 1.07
A liposome-based nanostructure for aptamer directed delivery. Chem Commun (Camb) (2009) 1.07
siRNA-aptamer chimeras on nanoparticles: preserving targeting functionality for effective gene silencing. ACS Nano (2011) 1.07
Prostate cancer cell death produced by the co-delivery of Bcl-xL shRNA and doxorubicin using an aptamer-conjugated polyplex. Biomaterials (2010) 1.07
Release of photoactivatable drugs from plasmonic nanoparticles for targeted cancer therapy. ACS Nano (2011) 1.06
AS1411 aptamer tagged PLGA-lecithin-PEG nanoparticles for tumor cell targeting and drug delivery. Biotechnol Bioeng (2012) 1.06
DNA aptamer functionalized nanomaterials for intracellular analysis, cancer cell imaging and drug delivery. Curr Opin Chem Biol (2012) 1.05
Selection of DNA ligands for protein kinase C-delta. Chem Commun (Camb) (2006) 1.04
Second-generation aptamer-conjugated PSMA-targeted delivery system for prostate cancer therapy. Int J Nanomedicine (2011) 1.04
Engineering of switchable aptamer micelle flares for molecular imaging in living cells. ACS Nano (2013) 1.03
Density dependence across multiple life stages in a temperate old-growth forest of northeast China. Oecologia (2012) 1.03
The therapeutic potential of cell-internalizing aptamers. Curr Top Med Chem (2009) 0.99
Cell-SELEX Technology. Biores Open Access (2012) 0.98
In vivo SELEX for Identification of Brain-penetrating Aptamers. Mol Ther Nucleic Acids (2013) 0.98
Selective activation of anticancer prodrugs by monoclonal antibody-enzyme conjugates. Adv Drug Deliv Rev (2001) 0.97
Aptamers as tools for target validation. Curr Opin Chem Biol (2005) 0.97
Use of oligonucleotide aptamer ligands to modulate the function of immune receptors. Clin Cancer Res (2013) 0.96
A nanocomplex that is both tumor cell-selective and cancer gene-specific for anaplastic large cell lymphoma. J Nanobiotechnology (2011) 0.95
An ultra pH-sensitive and aptamer-equipped nanoscale drug-delivery system for selective killing of tumor cells. Small (2013) 0.95